ReviewFrontiers in oncology2026
Cancer-associated fibroblasts in the lung cancer microenvironment from multi-dimensional mechanisms to therapeutic strategies.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, and therapeutic outcomes are frequently compromised by drug resistance and the complex tumor microenvironment. Although malignant progression is fundamentally driven by genetic alterations, cancer-associated fibroblasts (CAFs) have emerged as critical regulators of tumor progression, immune evasion, and therapeutic resistance. Main body: This review systematically summarizes the multidimensional roles of CAFs in lung cancer pathogenesis. CAFs remodel the extracellular matrix to generate high-stiffness stromal barriers, thereby activating the Integrin/Focal adhesion kinase (FAK)/Yes-associated protein (YAP) mechanotransduction axis and impairing drug delivery. Through a multifaceted secretome that includes Interleukin-6 (IL-6), Transforming growth factor-beta (TGF-β), Hepatocyte growth factor (HGF), and C-X-C motif chemokine ligand 12 (CXCL12), CAFs promote epithelial-mesenchymal transition and non-cell-autonomous resistance. Recent single-cell and spatial transcriptomic studies have further revealed functionally distinct CAF subpopulations associated with matrix remodeling, immune exclusion, and therapeutic response. In addition, CAF-derived small extracellular vesicles (sEVs) mediate bidirectional communication with tumor and immune cells, reinforcing tumor plasticity and immune evasion. CAFs also contribute to T-cell exclusion and suppressive myeloid-cell recruitment, thereby attenuating the efficacy of immune checkpoint blockade. Finally, we critically evaluate emerging therapeutic strategies targeting CAF-mediated pathways and discuss their translational opportunities and limitations. Conclusions: Overcoming CAF-mediated resistance requires a shift from non-selective stromal depletion toward biomarker-guided stromal normalization and subtype-specific interventions. By integrating mechanistic and translational evidence, this review provides a comprehensive framework for developing more effective precision therapies in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.